terça-feira, 6 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 27, 2025

XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move?

View original at finance.yahoo.com
XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move? Tsikhanovich Alena / Shutterstock.com Quick Read XRP rallied 1,200% in 6 weeks (December 2017): $0.25 to $3.30 driven by retail FOMO, exchange listings, Bitcoin hitting $20K…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A repeat of the 1,200% rally is possible in December 2025 if catalysts, sentiment, adoption, and structure align

    80% confidence

  • 2025 replaces retail mania with institutional firepower: $1.1B ETF inflows in 4 weeks, SEC settlement August 2025, RLUSD at $1B market cap

    80% confidence

  • XRP rallied 1,200% in 6 weeks from December 2017, driven by retail FOMO, exchange listings, and Bitcoin hitting $20K

    80% confidence

  • Steady 50-100% gains could push XRP to $3-4 by mid-2026, or price could remain range-bound between $1.80-$2.50 as institutions accumulate slowly

    80% confidence

  • 2017 had zero institutional participation vs measured allocations in 2025; no regulatory clarity vs SEC settlement; pure speculation vs banks using ODL ($1.3B quarterly)

    80% confidence

  • Over 1.35 billion XRP tokens have been removed from circulation into long-term custody, representing 45% less supply available for sale

    80% confidence

  • Social media was flooded with 'XRP to $10' predictions during the 2017 rally

    80% confidence

Data points we hold from this source

XRP · circulating supply reduction1.35 billion_tokens
XRP · stock price range1.80-2.20 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
XRP’s Historic December 2017 Surge Revisited—Could 2025 Set Up a Similar Move? — Source | Via News | pt.VIA.NEWS